Pharmaceuticals News and Research

RSS

Progen receives Nasdaq delisting notification

Progen Pharmaceuticals Limited today received notice from the Nasdaq Stock Market that its securities will be delisted due to a minimum bid price deficiency under Nasdaq Listing Rule 5500(a)(2).

24 Jun 2010

BioSante closes $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

24 Jun 2010

Obama to insurers: Health reform no excuse for big rate hikes

President Barack Obama warned a dozen large insurers not to use the new health law as an excuse for boosting premium rates at a White House meeting Tuesday, The Washington Post reports. After acknowledging that insurers weren't solely responsible for rising medical costs, the president said, "we've got to make sure this new law is not being used as an excuse to simply drive up costs.

24 Jun 2010

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

Tikcro Technologies Ltd. today reported results for the first quarter ended March 31, 2010.

24 Jun 2010

Watson's ANDA for Fentanyl Citrate Buccal tablets receives tentative FDA approval

Watson Pharmaceuticals, Inc. announced that its subsidiary, Watson Laboratories, Inc. has received tentative approval today from the United States (U.S.) Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Fentanyl Citrate Buccal tablets, 100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg and 800 mcg.

24 Jun 2010

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).

23 Jun 2010

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246®, SIGA's lead smallpox antiviral drug candidate.

23 Jun 2010

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Valeant Pharmaceuticals International today announced that Oxsoralen-Ultra, its therapy for severe psoriasis, is now available again in the United States on a limited supply basis.

23 Jun 2010

$Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors$

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.

23 Jun 2010

Grant introduces new range of digital, analogue ultrasonic benchtop baths

Grant Instruments, a world-renowned supplier of scientific, life sciences and data acquisition products, has unveiled an advanced range of high quality, robust, fully-featured digital and analogue ultrasonic benchtop baths. The baths are designed to meet the growing need for reliable ultrasonic cleaning in laboratories and across pharmaceutical, medical, healthcare and industrial applications.

23 Jun 2010

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, June 25 from 3:30 to 4:00 pm PT. The presentation will show that the Company's investigational LEVADEX™ orally inhaled migraine therapy was effective irrespective of when it was administered during a migraine cycle.

23 Jun 2010

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies and miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today that they have formed a strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease.

23 Jun 2010

EUCODIS Bioscience launches high-performance beta-lactamase

EUCODIS Bioscience, a developer and manufacturer of customized enzymes today announced that it has launched a high-performance beta-lactamase designed to inactivate a broad range of beta-lactam antibiotics. EUCODIS Bioscience is marketing the product under the LacBuster(TM) brand.

23 Jun 2010

German IVF Register reports one-millionth treatment cycle in reproductive medicine

Dr. Klaus Buhler, President of the German IVF Register, has reported the one-millionth treatment cycle in reproductive medicine recorded by the IVF Register in Germany this year. Presently, ninety per cent of all centers for in-vitro fertilization (IVF) in Germany collect data from reproductive treatments using RecDate Advance by Merck Serono - a database system developed by the IT consulting firm CRITEX, and marketed under the name MedITEX IVF.

23 Jun 2010

BioWa signs two licensing agreements with GSK

BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline. BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity. The second license agreement provides GSK with access to BioWa's COMPLEGENT Technology for enhancing the complement-dependent cytotoxicity of select GSK therapeutic antibodies.

23 Jun 2010

imec researchers demonstrate biosensors that detect extremely low concentrations of disease markers

Researchers at the nanotechnology research centre imec have demonstrated biosensors based on novel nanostructure geometries that increase the sensitivity and allow to detect extremely low concentrations of specific disease markers. This paves the way to early diagnostics of for example cancer by detecting low densities of cancer markers in human blood samples.

23 Jun 2010

Engineering and Physical Sciences Research Council awards £1.2 million to Bilayer Platform project

Scientists at the University of Southampton and Birkbeck College, University of London are developing a platform consisting of an array of artificial cell membranes that will enable more efficient testing of potential new drugs.

23 Jun 2010

K-State chemical engineer patents chemical structure to make natural personal care products in lab

A Kansas State University chemical engineer has developed and patented a chemical structure to make all-natural personal care products and purer pharmaceuticals in the laboratory.

23 Jun 2010

Update on Regulus and sanofi-aventis collaboration

Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. announced today that, as a result of the newly formed alliance Regulus has established with sanofi-aventis, each company will receive a payment of $1.8 million from Regulus. This represents 7.5% of the $25 million upfront payment from sanofi-aventis to Regulus.

23 Jun 2010

Misperceptions about 'light,' 'low,' 'mild' cigarettes

Today, new legislation will go into effect surrounding the ban of word descriptors such as "light," "low," and "mild" on all packaging and advertising of existing cigarettes and smokeless products. However, a new survey, sponsored by GlaxoSmithKline (GSK) Consumer Healthcare, shows that many smokers will choose the cigarettes in lighter-colored packaging because they incorrectly believe these cigarettes would be less harmful to their health or make it easier to quit smoking.

23 Jun 2010

Pharmaceuticals News and Research

Progen receives Nasdaq delisting notification

BioSante closes $15 million registered direct offering

Obama to insurers: Health reform no excuse for big rate hikes

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

Watson's ANDA for Fentanyl Citrate Buccal tablets receives tentative FDA approval

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Grant introduces new range of digital, analogue ultrasonic benchtop baths

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

EUCODIS Bioscience launches high-performance beta-lactamase

German IVF Register reports one-millionth treatment cycle in reproductive medicine

BioWa signs two licensing agreements with GSK

imec researchers demonstrate biosensors that detect extremely low concentrations of disease markers

Engineering and Physical Sciences Research Council awards £1.2 million to Bilayer Platform project

K-State chemical engineer patents chemical structure to make natural personal care products in lab

Update on Regulus and sanofi-aventis collaboration

Misperceptions about 'light,' 'low,' 'mild' cigarettes

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence